Deployment of a process digital twin of a pharmaceutical process with orchestrated interaction between online sensors and hybrid models enables innovative development and enhanced control of the production process.
Reduce time to market
creating economies of scale and optimum use of resources
Lower costs through reduced waste
up to 20% savings
Ensure high quality of products
increase of up to 10% product-margin
Process Digital Twin
With 2-3 million deaths prevented every year by vaccination, it is more important than ever to accelerate time to market, reduce batch waste and increase quality and reliability in pharmaceutical manufacturing.
To address these challenges, Atos, GlaxoSmithKline and Siemens have come together to bring digital transformation to pharmaceutical development and manufacturing. Using in-line sensors at each step in the process, it is now possible to collect data to understand exactly what is happening in real-time. Combining this data with physical, chemical and biological models we’ve built a digital twin of the pharmaceutical process; a live in-silica replica of the physical process which enables optimization of operations and the simulation of changes, providing new insights for development and full control over the pharmaceutical manufacturing process.
Global pharmaceutical companyThe quality of the product could only be measured once it had been produced. If it didn’t meet the set critical quality criteria the batch would be discarded. A new way of monitoring and measuring quality throughout the production process ensures that the specification is correctly implemented. Additionally data generated by the process provides insight, allowing in-line adjustments to be made to the process to ensure the end product meets quality standards and that the performance of the process continues to improve. Thanks to the ability to experiment in-silico with the process we are able to significantly reduce the amount of resources spent in experimentation.
Tackle your business challenges
Book your dedicated workshop
In the face of the COVID-19 pandemic, the world is waiting for an effective vaccine as the only sustainable way to prevent the disease. With between two and three million deaths prevented every year by vaccination, only clean drinking water rivals its ability to save lives.
Atos is collaborating with the digitalization expert Siemens and the global healthcare company GSK to digitalize vaccine development and production process. The digital twin plays a vital role in achieving shorter development cycles for vaccines, and optimize the time the vaccines reach people- with optimum quality.
Together with GSK, a science-led global healthcare company, and Siemens- one of the world’s leading digital transformation companies, we have piloted a Digital Twin- an end-to-end and real- time simulation of the entire vaccine manufacturing process. Every step from the vaccine development to distribution and clinical trials takes time that can be optimized, and we are embracing the digitalization to help speed up the process.
Digital twin, a virtual and connected model of the manufacturing process, can help speed up drug and vaccine development. Find out more about the role of digital twins in pharma manufacturing and R&D, the technology behind it, and hear the case study of a global vaccine provider.
Dr. Natalija Krivokapić
Head of Global IoT at Atos
Global Portfolio Head, Healthcare and Life Sciences